KANNT, Aimo,BIELOHUBY, Maximilian,ELVERT, Ralf,WAGNER, Michael,BOSSART, Martin,HAACK, Torsten,KEIL, Stephanie,SEIZ, Werner
申请号：
AU2018314773
公开号：
AU2018314773A1
申请日:
2018.08.08
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The present invention relates to the medical use of specific GLP-1 /glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
